大剂量呋塞米持续静脉泵入治疗重度心衰临床疗效分析
|
摘要
目的分析大剂量呋塞米持续静脉泵入治疗重度心衰的临床有效性。方法选取2017年5月至2018年5月期间本院诊治的60例重度心衰患者并根据治疗方法分为对照组(常规静脉推注呋塞米)、研究组(持续静脉泵入大剂量呋塞米),比对两组治疗效果。结果研究组LVEDD、LVEF水平优于对照组(P<0.05),研究组治疗后气促改善时间、水肿消退时间、平均住院天数均优于对照组(P<0.05),研究组治疗后总有效率高于对照组(P<0.05)。结论大剂量呋塞米持续静脉泵入治疗重度心衰的临床效果显著,可推广。
Objective To analyze the clinical efficacy of continuous intravenous infusion of high-dose furosemide in the treatment of severe heart failure. Methods In May 2017-May 2018, our hospital make a diagnosis and give treatment of 60 patients with severe heart failure and according to the treatment methods are divided into the control group(conventional intravenous push note cefuroxime Sammy), group(continuous intravenous pumping large dose furosemide Sammy), comparing two groups of therapeutic effect. Results The team LVEDD, LVEF level is better than that of control group(P<0.05), the team shortness of breath improved after treatment time, edema, fade time, average hospitalization days were better than control group(P<0.05), the team after treatment the total effective rate was higher than control group(P<0.05). Conclusion Continuous intravenous infusion of high-dose furosemide in the treatment of severe heart failure is effective and can be popularized.
Objective To analyze the clinical efficacy of continuous intravenous infusion of high-dose furosemide in the treatment of severe heart failure. Methods In May 2017-May 2018, our hospital make a diagnosis and give treatment of 60 patients with severe heart failure and according to the treatment methods are divided into the control group(conventional intravenous push note cefuroxime Sammy), group(continuous intravenous pumping large dose furosemide Sammy), comparing two groups of therapeutic effect. Results The team LVEDD, LVEF level is better than that of control group(P<0.05), the team shortness of breath improved after treatment time, edema, fade time, average hospitalization days were better than control group(P<0.05), the team after treatment the total effective rate was higher than control group(P<0.05). Conclusion Continuous intravenous infusion of high-dose furosemide in the treatment of severe heart failure is effective and can be popularized.
引文
[1]王志敏,张飚,李作卿,等.大剂量呋塞米持续静脉泵入在重度心衰患者临床治疗中的应用[J].海南医学,2017,28(4):637-638.
[2]王伟灿,陈亭杰,赵孝,等.大剂量呋塞米持续静脉泵入治疗重度心衰临床疗效观察[J].中国卫生标准管理,2017,8(11):95-96.
[3]李飞,贾勇,薛凌,等.缬沙坦对高血压心脏病中-重度心衰患者心功能和炎症因子水平的影响[J].中国老年学杂志,2018,38(1):75-77.
[4]傅庆华,郑昭芬.IABP辅助治疗对急性ST段抬高型心肌梗死合并重度心衰患者预后的影响[J].医学临床研究,2016,33(4):758-760.
[5]祁学成,李霞,黄小婷,等.血浆氨基末端B型利钠肽原水平监测对中重度心衰患者应用琥珀酸美托洛尔治疗的指导价值[J].医学临床研究,2016,33(9):1841-1843.
[6]汤学勤,武雪亮,项保利,等.呋塞米联合依那普利对慢性肺源性心脏病心力衰竭的临床研究[J].中国临床药理学杂志,2016(3):198-201.
[7]王立立,耿彦平,杨倩,等.托伐普坦联合呋塞米治疗老年慢性心力衰竭利尿剂抵抗患者的疗效观察[J].中华老年心脑血管病杂志,2018,20(2):158-160.
[8]夏科君,单淑琴,赵蓓,等.酚妥拉明联合呋塞米对肺炎伴心力衰竭患儿EDV、ESV水平及心电图的影响[J].中国生化药物杂志,2017(4):278-280.
[9]周文来.大剂量呋塞米对早期急性肾损伤伴少尿患者生化指标及不良反应的影响[J].广西医科大学学报,2016,33(3):546-548.
[10]张慧,蔡尚郎,姜先雁,等.50%葡萄糖静注联合呋塞米治疗顽固性心力衰竭疗效分析[J].现代生物医学进展,2016,16(4):705-708.
[11]王伟,边瓯,马宁,等.小剂量托伐普坦联合呋塞米治疗急性心力衰竭合并利尿剂抵抗超高龄老年患者临床评价[J].临床军医杂志,2016,44(6):601-604.
[12]冯迎军.前列地尔联合高压氧治疗先天性心脏病伴重度肺动脉高压的临床效果观察[J].社区医学杂志,2016,14(6):35-37.
[13]宋艳茹.硝普钠与多巴胺和呋塞米合用治疗顽固性心衰疗效观察[J].中国现代药物应用,2016,10(7):116-117.
[2]王伟灿,陈亭杰,赵孝,等.大剂量呋塞米持续静脉泵入治疗重度心衰临床疗效观察[J].中国卫生标准管理,2017,8(11):95-96.
[3]李飞,贾勇,薛凌,等.缬沙坦对高血压心脏病中-重度心衰患者心功能和炎症因子水平的影响[J].中国老年学杂志,2018,38(1):75-77.
[4]傅庆华,郑昭芬.IABP辅助治疗对急性ST段抬高型心肌梗死合并重度心衰患者预后的影响[J].医学临床研究,2016,33(4):758-760.
[5]祁学成,李霞,黄小婷,等.血浆氨基末端B型利钠肽原水平监测对中重度心衰患者应用琥珀酸美托洛尔治疗的指导价值[J].医学临床研究,2016,33(9):1841-1843.
[6]汤学勤,武雪亮,项保利,等.呋塞米联合依那普利对慢性肺源性心脏病心力衰竭的临床研究[J].中国临床药理学杂志,2016(3):198-201.
[7]王立立,耿彦平,杨倩,等.托伐普坦联合呋塞米治疗老年慢性心力衰竭利尿剂抵抗患者的疗效观察[J].中华老年心脑血管病杂志,2018,20(2):158-160.
[8]夏科君,单淑琴,赵蓓,等.酚妥拉明联合呋塞米对肺炎伴心力衰竭患儿EDV、ESV水平及心电图的影响[J].中国生化药物杂志,2017(4):278-280.
[9]周文来.大剂量呋塞米对早期急性肾损伤伴少尿患者生化指标及不良反应的影响[J].广西医科大学学报,2016,33(3):546-548.
[10]张慧,蔡尚郎,姜先雁,等.50%葡萄糖静注联合呋塞米治疗顽固性心力衰竭疗效分析[J].现代生物医学进展,2016,16(4):705-708.
[11]王伟,边瓯,马宁,等.小剂量托伐普坦联合呋塞米治疗急性心力衰竭合并利尿剂抵抗超高龄老年患者临床评价[J].临床军医杂志,2016,44(6):601-604.
[12]冯迎军.前列地尔联合高压氧治疗先天性心脏病伴重度肺动脉高压的临床效果观察[J].社区医学杂志,2016,14(6):35-37.
[13]宋艳茹.硝普钠与多巴胺和呋塞米合用治疗顽固性心衰疗效观察[J].中国现代药物应用,2016,10(7):116-117.